PRESS & NEWS
Prevail Therapeutics PR006 Trial Discontinued
While the PR006 program has been discontinued, research into FTD continues. Here’s what this update means for the community and the path forward.
Prevail Therapeutics has announced that it is discontinuing development of PR006, an investigational treatment for frontotemporal degeneration related to progranulin (GRN) gene variants. The decision followed a review of clinical trial data showing that, while the treatment was generally safe, it did not demonstrate sufficient benefit in the group studied.
While this news may feel disappointing for individuals and families impacted by FTD, research setbacks are a normal and important part of progress. Each clinical study contributes valuable knowledge that helps researchers better understand the disease and informs future approaches.
The contributions of trial participants remain deeply important. Their involvement helps move the field forward and supports the development of future research efforts, even when a specific program does not continue.
Research into FTD, including GRN-related forms, is ongoing. Participation in the FTD Disorders Registry helps demonstrate a research-ready community and supports future studies and trials.
For more details about the PR006 decision, read the full update from The Association for Frontotemporal Degeneration (AFTD).
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.